Company Overview and News

 
A Difficult Quarter For Advantage Oil & Gas

2018-08-21 seekingalpha
The company is trying to adapt by producing more NGL and by selling some gas away from Alberta.
AAV AAV

 
Advantage Oil & Gas (AAV) Reports Q2 Loss, Lags Revenue Estimates

2018-08-03 zacks
Advantage Oil & Gas (AAV - Free Report) just came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.01. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.
CY AAV AAV

76
Zacks Industry Outlook Highlights: Pioneer Energy, Advantage Oil and Parker Drilling

2018-06-19 zacks
Chicago, IL – June 19, 2018 – Today, Zacks Equity Research discusses the Oil & Gas, including Pioneer Energy Services Corp. (PES - Free Report) , Advantage Oil & Gas Ltd. (AAV - Free Report) and Parker Drilling Company (PKD - Free Report) .
JAZZ BSX AAV FIX KMG PKD BAX AAV GIII PES NSIT

13
Oil and Gas - Drilling Stock Outlook: Too Many Negative Catalysts

2018-06-18 zacks
The uptick in tendering activity and contract fixtures over the past few months notwithstanding, the oil drilling industry is not in a good health. Waiting for that ‘elusive' recovery for about three years, the current oilfield environment remains one of the most difficult ones. With new competitors entering the market and drilling contractors too rattled to make new investment decisions, rig owners have seen a number of their vessels get idled.
HD AAV PKD AAV PES

 
Advantage Oil & Gas Valuation Relies On Gas Price And Production Improvements

2018-06-12 seekingalpha
Thanks to its concentrated assets, Advantage Oil and Gas produces natural gas in Canada at low cost.
AAV AAV

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:AAV / Advantage Oil & Gas Ltd. on message board site Silicon Investor.

AAVG AAVG AAVG Aavdex Corporation Aavdex Corporation Aavdex Corporation
Aavid Thermal Technologies (AATT) Aavid Thermal Technologies (AATT) Aavid Thermal Technologies (AATT)